European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.
Détails
ID Serval
serval:BIB_89F413CA6F8C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Lettre (letter): communication adressée à l'éditeur.
Collection
Publications
Institution
Titre
European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.
Périodique
Journal of the European Academy of Dermatology and Venereology
ISSN
1468-3083 (Electronic)
ISSN-L
0926-9959
Statut éditorial
Publié
Date de publication
05/2021
Peer-reviewed
Oui
Volume
35
Numéro
5
Pages
e308-e311
Langue
anglais
Notes
Publication types: Letter
Publication Status: ppublish
Publication Status: ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic is caused by rapid spread of different strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity of infection ranges from mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper respiratory illness, loss of smell and taste, pneumonia, severe acute respiratory syndrome, and multi-organ failure. Risk factors for a severe or lethal course include age, male gender, obesity, diabetes, cardiovascular disease, and immune suppression <sup>1</sup> .
Mots-clé
Adult, Biological Products, COVID-19, Dermatitis, Atopic/drug therapy, Humans, SARS-CoV-2, Vaccination
Pubmed
Web of science
Open Access
Oui
Création de la notice
22/02/2021 10:57
Dernière modification de la notice
30/05/2021 5:35